1. ROS1 Translocations and NSCLC

2. Introduction

3. Introduction

4. Unique Features of ROS1-Rearranged NSCLC

5. Pathophysiology of ROS1

6. Identifying Appropriate Patients for ROS1 Testing in NSCLC

7. Identifying Appropriate Patients for ROS1 Testing in NSCLC

8. Methods for Detecting ROS1 Rearrangements

9. Crizotinib in ROS1-Rearranged NSCLC Overview

10. Crizotinib The PROFILE 1001 Trial

11. Crizotinib OxOnc, EUROS1, and the Metro Case Series

12. Crizotinib and Brain Metastases

13. Crizotinib Grade 3 TRAEs in ≥ 10% of Patients in the PROFILE 1001 Trial

14. Ceritinib in ROS1-Rearranged NSCLC Overview

15. Ceritinib Phase 2, Open-Label Trial

16. Entrectinib in ROS1-Rearranged NSCLC Overview and Integrated Dataset

17. Resistance to Crizotinib in ROS1-Rearranged NSCLC

18. Lorlatinib in ROS1-Rearranged NSCLC Overview

19. Lorlatinib Phase 2 ALK Registration Trial

20. Lorlatinib Phase 2 ALK Registration Trial (cont)

21. Repotrectinib in ROS1-Rearranged NSCLC Overview

22. Repotrectinib TRIDENT-1 Trial

23. Cabozantinib and Foretinib in ROS1-Positive NSCLC Overview

24. Considerations for Choosing Second-Line Therapy in ROS1-Rearranged NSCLC

25. Closing Remarks

26. Abbreviations

27. Abbreviations (cont)